SUSAN CUCCIARDI: Open Payments
NPI 1528271467 · SILVERDALE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,388 in 71 payments from 19 companies in 2025. Trend: 2023 $1,393 · 2024 $1,645 · 2025 $1,388
Food & beverage: $1,388
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 15 | $312 |
| GlaxoSmithKline, LLC. | 19 | $288 |
| AstraZeneca Pharmaceuticals LP | 12 | $256 |
| Grifols USA, LLC | 4 | $102 |
| Regeneron Healthcare Solutions, Inc. | 3 | $56 |
| Insmed, Inc. | 2 | $43 |
| PFIZER INC. | 2 | $43 |
| Amgen Inc. | 2 | $42 |
| Vifor Pharma, Inc. | 2 | $37 |
| Merck Sharp & Dohme LLC | 1 | $34 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, TEZSPIRE, Prolastin-C Liquid, FASENRA, AIRSUPRA, Arikayce.
Industry payments across WA — which companies pay providers there.
